<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Chronic hepatitis B related hepatocellular carcinoma (HCC) is a leading cause of cancer death in hepatitis B virus endemic areas including the Asia-Pacific region. The risk of HCC development can be reduced by antiviral therapy and surveillance programs. However, this would place a heavy fiscal burden on low- and middle-income countries, which are in these endemic areas. Therefore, there is a need for accurate prediction of HCC risk to prioritize patient care. Based on well-established host and viral risk factors, several HCC risk scores have been derived and validated: GAG-HCC, CU-HCC, and REACH-B for Asians and PAGE-B for white people of European ancestry. Each score has been shown to be accurate in predicting HCC up to 10 years into the future when applied to the appropriate patient group, especially with regards to their ethnicity and antiviral therapy status. Recently noninvasive tests of liver fibrosis have been integrated into existing HCC risk scores with encouraging results. As HCC risk prediction continues to evolve, the future promises a more individualized approach to HCC surveillance, ultimately leading to improved patient care and resource allocation.</p>
</abstract>

Chronic hepatitis B related hepatocellular carcinoma (HCC) is a leading cause of cancer death in hepatitis B virus endemic areas including the Asia-Pacific region. The risk of HCC development can be reduced by antiviral therapy and surveillance programs. However, this would place a heavy fiscal burden on low- and middle-income countries, which are in these endemic areas. Therefore, there is a need for accurate prediction of HCC risk to prioritize patient care. Based on well-established host and viral risk factors, several HCC risk scores have been derived and validated: GAG-HCC, CU-HCC, and REACH-B for Asians and PAGE-B for white people of European ancestry. Each score has been shown to be accurate in predicting HCC up to 10 years into the future when applied to the appropriate patient group, especially with regards to their ethnicity and antiviral therapy status. Recently noninvasive tests of liver fibrosis have been integrated into existing HCC risk scores with encouraging results. As HCC risk prediction continues to evolve, the future promises a more individualized approach to HCC surveillance, ultimately leading to improved patient care and resource allocation.

Current trends in the risk prediction for hepatitis B virus-related hepatocellular carcinoma

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Chronic hepatitis B related hepatocellular carcinoma (HCC) is a leading cause of cancer death in hepatitis B virus endemic areas including the Asia-Pacific...

Current trends in the risk prediction for hepatitis B virus-related hepatocellular carcinoma

Article Category: Mini review article

Publicado en línea: 31 ene 2017

Páginas: 3 - 13

DOI: https://doi.org/10.5372/1905-7415.1001.459

Palabras clave
Albumin, antiviral therapy, cirrhosis, entecavir, transient elastography

© 2016 Ken Liu, Grace Lai-Hung Wong, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Current trends in the risk prediction for hepatitis B virus-related hepatocellular carcinoma

Article Category: Mini review article

Publicado en línea: 31 ene 2017

Páginas: 3 - 13

DOI: https://doi.org/10.5372/1905-7415.1001.459

Palabras claveAlbumin, antiviral therapy, cirrhosis, entecavir, transient elastography

© 2016 Ken Liu, Grace Lai-Hung Wong, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
Albumin, antiviral therapy, cirrhosis, entecavir, transient elastography